Pathway-dependent inhibition of paclitaxel hydroxylation by kinase inhibitors and assessment of drug-drug interaction potentials

Drug Metabolism and Disposition

Volumn 42, Issue 4, 2014, Pages 782-795

  Wang, Yedong ^a   Wang, Meiyu ^a   Qi, Huixin ^a   Pan, Peichen ^a   Hou, Tingjun ^a   Li, Jiajun ^a   He, Guangzhao ^a   Zhang, Hongjian ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; AXITINIB; BOSUTINIB; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; DASATINIB; ERLOTINIB; GEFITINIB; HYDROGEN; IMATINIB; LAPATINIB; NILOTINIB; PACLITAXEL; PAZOPANIB; PROTEIN KINASE INHIBITOR; SORAFENIB; SUNITINIB;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG INHIBITION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; LIVER MICROSOME; MOLECULAR DOCKING; PREDICTION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HUMANS; HYDROXYLATION; MICROSOMES, LIVER; MOLECULAR DOCKING SIMULATION; PACLITAXEL; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; TANDEM MASS SPECTROMETRY;

EID: 84896137206     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.053793     Document Type: Article

References (60)

1. Bergmann TK, Gréen H, Brasch-Andersen C, Mirza MR, Herrstedt J, Hølund B, du Bois A, Damkier P, Vach W, and Brosen K, et al. (2011) Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol 67:693-700.
2. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, and Bourne PE (2000) The protein data bank. Nucleic Acids Res 28:235-242. (Pubitemid 30047768)
3. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, and Ni L, et al.; Pharmaceutical Research and Manufacturers of America Drug Metabolism/Clinical Pharmacology Technical Working Groups (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 43:443-469. (Pubitemid 36506147)
4. Burris HA, 3rd, Dowlati A, Moss RA, Infante JR, Jones SF, Spigel DR, Levinson KT, Lindquist D, Gainer SD, and Dar MM, et al. (2012) Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors. Mol Cancer Ther 11:1820-1828.
5. Chiba M, Tang C, Neway WE, Williams TM, Desolms SJ, Dinsmore CJ, Wai JS, and Lin JH (2001) P450 interaction with farnesyl-protein transferase inhibitors metabolic stability, inhibitory potency, and P450 binding spectra in human liver microsomes. Biochem Pharmacol 62:773-776. (Pubitemid 32816995)
6. Dahal UP, Joswig-Jones C, and Jones JP (2012) Comparative study of the affinity and metabolism of type I and type II binding quinoline carboxamide analogues by cytochrome P450 3A4. J Med Chem 55:280-290.
7. de Graan AJ, Elens L, Sprowl JA, Sparreboom A, Friberg LE, van der Holt B, de Raaf PJ, de Bruijn P, Engels FK, and Eskens FA, et al. (2013) CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin Cancer Res 19:3316-3324.
8. Desai PB, Duan JZ, Zhu YW, and Kouzi S (1998) Human liver microsomal metabolism of paclitaxel and drug interactions. Eur J Drug Metab Pharmacokinet 23:417-424. (Pubitemid 28517731)
9. i. Biochem J 129:197-202.
10. Esteva FJ, Franco SX, Hagan MK, Brewster AM, Somer RA, Williams W, Florance AM, Turner S, Stein S, and Perez A (2013) An open-label safety study of lapatinib plus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer. Oncologist 18:661-666.
11. Fahmi OA, Maurer TS, Kish M, Cardenas E, Boldt S, and Nettleton D (2008) A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos 36:1698-1708.
12. Filppula AM, Laitila J, Neuvonen PJ, and Backman JT (2012) Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol 165:2787-2798.
13. Fransson MN, Gréen H, Litton JE, and Friberg LE (2011) Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model. Drug Metab Dispos 39:247-255.
14. Guest EJ, Aarons L, Houston JB, Rostami-Hodjegan A, and Galetin A (2011) Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions. Drug Metab Dispos 39:170-173.
15. Hertz DL, Motsinger-Reif AA, Drobish A, Winham SJ, McLeod HL, Carey LA, and Dees EC (2012) CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat 134:401-410.
16. Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, Carey LA, and Dees EC (2013) CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol 24:1472-1478.
17. Huang S-M, Temple R, Throckmorton DC, and Lesko LJ (2007) Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 81:298-304. (Pubitemid 46174829)
18. Hsyu PH, Mould DR, Upton RN, and Amantea M (2013) Pharmacokinetic- pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia. Cancer Chemother Pharmacol 71:209-218.
19. Isin EM and Guengerich FP (2006) Kinetics and thermodynamics of ligand binding by cytochrome P450 3A4. J Biol Chem 281:9127-9136. (Pubitemid 43864626)
20. Ito K, Hallifax D, Obach RS, and Houston JB (2005) Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 33:837-844. (Pubitemid 40686638)
21. Kaminski GA, Friesner RA, Tirado-Rives J, and Jorgensen WL (2001) Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J Phys Chem B 105:6474-6487 DOI: 10.1021/jp003919d. (Pubitemid 35339015)
22. Kenny JR, Mukadam S, Zhang C, Tay S, Collins C, Galetin A, and Khojasteh SC (2012) Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction. Pharm Res 29:1960-1976.
23. Kim MJ, Lee JW, Oh KS, Choi CS, Kim KH, Han WS, Yoon CN, Chung ES, Kim DH, and Shin JG (2013) The tyrosine kinase inhibitor nilotinib selectively inhibits CYP2C8 activities in human liver microsomes. Drug Metab Pharmacokinet 28:462-467.
24. Kirby BJ and Unadkat JD (2010) Impact of ignoring extraction ratio when predicting drug-drug interactions, fraction metabolized, and intestinal first-pass contribution. Drug Metab Dispos 38:1926-1933.
25. Kozloff M, Chuang E, Starr A, Gowland PA, Cataruozolo PE, Collier M, Verkh L, Huang X, Kern KA, and Miller K (2010) An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol 21:1436-1441.
26. Larson RA, Yin OQ, Hochhaus A, Saglio G, Clark RE, Nakamae H, Gallagher NJ, Demirhan E, Hughes TP, and Kantarjian HM, et al. (2012) Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol 68:723-733.
27. Leskelä S, Jara C, Leandro-García LJ, Martínez A, García-Donas J, Hernando S, Hurtado A, Vicario JC, Montero-Conde C, and Landa I, et al. (2011) Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J 11:121-129.
28. Li X, He Y, Ruiz CH, Koenig M, Cameron MD, and Vojkovsky T (2009a) Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways. Drug Metab Dispos 37:1242-1250.
29. Li X, Kamenecka TM, and Cameron MD (2009b) Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities. Chem Res Toxicol 22:1736-1742.
30. Li X, Kamenecka TM, and Cameron MD (2010) Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile. Drug Metab Dispos 38:1238-1245.
31. Lu C, Berg C, Prakash SR, Lee FW, and Balani SK (2008) Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. III. In vitro-in vivo correlation with fluconazole. Drug Metab Dispos 36:1261-1266. (Pubitemid 351929309)
32. Margolis JM and Obach RS (2003) Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions. Drug Metab Dispos 31:606-611. (Pubitemid 36444170)
33. Martin LP, Kozloff MF, Herbst RS, Samuel TA, Kim S, Rosbrook B, Tortorici M, Chen Y, Tarazi J, and Olszanski AJ, et al. (2012) Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. Br J Cancer 107:1268-1276.
34. Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, and Brem H (2007) Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 6:609-621. (Pubitemid 351308218)
35. Miller VA, Johnson DH, Krug LM, Pizzo B, Tyson L, Perez W, Krozely P, Sandler A, Carbone D, and Heelan RT, et al. (2003) Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. J Clin Oncol 21:2094-2100. (Pubitemid 46606357)
36. Monsarrat B, Mariel E, Cros S, Garès M, Guénard D, Guéritte-Voegelein F, and Wright M (1990) Taxol metabolism. Isolation and identification of three major metabolites of taxol in rat bile. Drug Metab Dispos 18:895-901.
37. Monsarrat B, Alvinerie P, Wright M, Dubois J, Guéritte-Voegelein F, Guénard D, Donehower RC, and Rowinsky EK (1993) Hepatic metabolism and biliary excretion of Taxol in rats and humans. J Natl Cancer Inst Monogr 15:39-46.
38. Monsarrat B, Chatelut E, Royer I, Alvinerie P, Dubois J, Dezeuse A, Roche H, Cros S, Wright M, and Canal P (1998) Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4. Drug Metab Dispos 26:229-233. (Pubitemid 28182398)
39. Murakami H, Tamura T, Takahashi T, Nokihara H, Naito T, Nakamura Y, Nishio K, Seki Y, Sarashina A, and Shahidi M, et al. (2012) Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Cancer Chemother Pharmacol 69:891-899.
40. Nagar S and Korzekwa K (2012) Commentary: nonspecific protein binding versus membrane partitioning: it is not just semantics. Drug Metab Dispos 40:1649-1652.
41. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348. (Pubitemid 41832613)
42. Okamoto I, Miyazaki M, Morinaga R, Kaneda H, Ueda S, Hasegawa Y, Satoh T, Kawada A, Fukuoka M, and Fukino K, et al. (2010) Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Invest New Drugs 28:844-853.
43. Polasek TM, Elliot DJ, Lewis BC, and Miners JO (2004) Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther 311:996-1007. (Pubitemid 39612704)
44. Pishvaian MJ, Slack R, Koh EY, Beumer JH, Hartley ML, Cotarla I, Deeken J, He AR, Hwang J, and Malik S, et al. (2012) A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy. Cancer Chemother Pharmacol 70:843-853.
45. Rowland Yeo K, Jamei M, Yang J, Tucker GT, and Rostami-Hodjegan A (2010) Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. Eur J Pharm Sci 39:298-309.
46. Schoch GA, Yano JK, Sansen S, Dansette PM, Stout CD, and Johnson EF (2008) Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem 283:17227-17237.
47. Secord AA, Teoh DK, Barry WT, Yu M, Broadwater G, Havrilesky LJ, Lee PS, Berchuck A, Lancaster J, and Wenham RM (2012) A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer. Clin Cancer Res 18:5489-5498.
48. Sevrioukova IF and Poulos TL (2012) Structural and mechanistic insights into the interaction of cytochrome P4503A4 with bromoergocryptine, a type I ligand. J Biol Chem 287:3510-3517.
49. Smorenburg CH, ten Tije AJ, Verweij J, Bontenbal M, Mross K, van Zomeren DM, Seynaeve C, and Sparreboom A (2003) Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. Eur J Cancer 39:196-202. (Pubitemid 36057070)
50. Sonnichsen DS, Liu Q, Schuetz EG, Schuetz JD, Pappo A, and Relling MV (1995) Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 275:566-575. (Pubitemid 26025545)
51. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Meijer DKF, Borst P, Nooijen WJ, Beijnen JH, and van Tellingen O (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:2031-2035. (Pubitemid 27113956)
52. Takakusa H, Wahlin MD, Zhao C, Hanson KL, New LS, Chan EC, and Nelson SD (2011) Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib. Drug Metab Dispos 39:1022-1030.
53. Taniguchi R, Kumai T, Matsumoto N, Watanabe M, Kamio K, Suzuki S, and Kobayashi S (2005) Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4. J Pharmacol Sci 97:83-90. (Pubitemid 40313103)
54. Teng WC, Oh JW, New LS, Wahlin MD, Nelson SD, Ho HK, and Chan EC (2010) Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol 78:693-703.
55. Tran HT, Zinner RG, Blumenschein GR, Jr, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum BL, and Herbst RS (2011) Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced non-small cell lung cancer (NSCLC). Invest New Drugs 29:499-505.
56. Walle T, Kumar GN, McMillan JM, Thornburg KR, and Walle UK (1993) Taxol metabolism in rat hepatocytes. Biochem Pharmacol 46:1661-1664. (Pubitemid 23338501)
57. Wattanachai N, Polasek TM, Heath TM, Uchaipichat V, Tassaneeyakul W, Tassaneeyakul W, and Miners JO (2011) In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6 a-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance. Eur J Clin Pharmacol 67:815-824.
58. Václavíková R, Horský S, Simek P, and Gut I (2003) Paclitaxel metabolism in rat and human liver microsomes is inhibited by phenolic antioxidants. Naunyn Schmiedebergs Arch Pharmacol 368:200-209. (Pubitemid 37255481)
59. Vermorken JB, Rottey S, Ehrnrooth E, Pelling K, Lahogue A, Wind S, and Machiels JP (2013) A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. Ann Oncol 24:1392-1400.
60. Zhang JW, Ge GB, Liu Y, Wang LM, Liu XB, Zhang YY, Li W, He YQ, Wang ZT, and Sun J, et al. (2008) Taxane's substituents at C3′ affect its regioselective metabolism: different in vitro metabolism of cephalomannine and paclitaxel. Drug Metab Dispos 36:418-426. (Pubitemid 351185756)